Skip to content

Current Status, Position

Dr Paul Cornes is an Oncologist from the UK and a full-time Cancer Researcher with the Comparative Outcomes Group. He was the plenary lecturer on Value and Economics for the last meeting of the Gastrointestinal Cancer Group of the European Society of Medical Oncology. He was in the steering group for the European School of Oncology programme on Access to Innovation in Cancer Treatment. His most recent book is “Fast Facts – Biosimilars in Haematology and Oncology” – co-written with Ali McBride, a US Hospital Pharmacist from Tucson, AZ.

Education

Dr Paul Cornes trained in medicine at Oxford University and in oncology at the Royal Marsden Hospital, London before taking a Consultant Post at Bristol & Bath, UK. He is currently part of the Cochrane Collaboration.

Research Area

Dr Paul Cornes has a special interest in health economics, affordable healthcare policy & practice. He has been on the expert panel for two biosimilar approvals at the FDA, and is a stakeholder with the European Commission Biosimilars Group and has written two recent books on the subject: fast facts, biosimilars and biosimilars in haematology and oncology.

Conflict of interest:

Dr Paul Cornes is on the advisory boards of Accord Healthcare. He also currently is on the advisory board and received speaker fees from Mylan-Biocon, Sandoz and Pfizer.

The European Comission covers for his travel expenses to attend meetings.

×

Deadline extended to July 15th

Problems caused by shortages are serious, threaten patient care and require urgent action.

Help us provide an overview of the scale of the problem, as well as insights into the impact on overall patient care.

Our aim is to investigate the causes of medicine and medical device shortages in the hospital setting,  while also gathering effective solutions and best practices implemented at local, regional, and national levels.

×

Join us in Prague for the 2nd edition of BOOST!

Secure your spot in the Movement for Shortage-Free World

BOOST is where visionaries, innovators, and healthcare leaders come together to tackle one of the biggest challenges in hospital pharmacy—medicine shortages.